HOUSTON and LONDON – Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is transforming the treatment of solid and hematological cancer by developing the next generation of CAR therapies.
Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
Cambridge, UK – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, confirms that it has commenced its human study being carried out on its SkinBiotix® technology.
Copenhagen, Denmark - Xellia Pharmaceuticals (Xellia or the Company), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has opened a new office in Buffalo Grove, near Chicago, Illinois to accommodate the Company’s expanding North American commercial organization.
Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, today announced it has entered into an agreement with a new strategic partner Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.
SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.
Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.
Cambridge, UK: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul.
Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.
Groningen, The Netherlands – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced that it has signed an agreement with Synovis Micro Companies Alliance Inc. (“Synovis MCA”), a subsidiary of Baxter International Inc., to be the exclusive distributor of its nerve capping device, NEUROCAP®, in the US.
Munich, Germany and Copenhagen, Denmark - Munich-based biotech company LEUKOCARE AG and Xellia Pharmaceuticals, a specialty pharmaceutical company providing important anti-infective treatments against serious and often life threatening infections, today announced a global strategic partnership to discover innovative formulations which will enable the development of value-added anti-infective products intended to enhance patient care.
Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for the period May-August 2018.
CAMBRIDGE, UK – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, is pleased to provide an update to its announcement of 16 August 2018. The stability criteria required for its human study has been met and the Company expects to commence the study in September as planned.
Cambridge, United Kingdom – Congenica, the global provider of clinical genomics interpretation software, today announced the appointment of Mrs Wendy Britten as its new Chief Financial Officer (CFO), effective 1st September, 2018. Mrs Britten will have overall control and responsibility for all financial aspects of the business and will play a key role in business development and fundraising activities.
LONDON, BOSTON, TOKYO – The first half of 2018 has seen biopharma IPOs and venture financing accelerate from the already-healthy levels witnessed in 2017. Deal making has dimmed further, however, raising concern that overheated valuations in certain pockets of the sector are putting off buyers.
Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA202, its second T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA202 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genetic engineering of the patient’s own T cells to express an exogenous TCR. The goal is to redirect and activate the T cells to treat solid tumors. The single-center clinical study is now open for enrollment at The University of Texas MD Anderson Cancer Center in Houston, Texas.
London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted as a finalist for the 2018 OBN Awards, in the category ‘Best Diagnostic Medtech Company’. These prestigious industry award nominations recognise and celebrate leading companies in the Life Sciences industry.
Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received its first order via GE Healthcare (GEHC) for TexRAD®, its patented image texture analysis technology.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the developer of targeted T-cell engagers, today announced that it has achieved another technical milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda; TSE:4502).
London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, today announced that it has been shortlisted for the inaugural 2018 Medtech Insight Awards, in the category ‘Most Innovative Team or Innovator of the Year’.
Cambridge, UK – Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has completed the GMP drug substance manufacture of an ABZENA Inside product that was originally humanised utilising Abzena’s Composite Human Antibody platform™. The product is a novel therapeutic antibody, Clevegen®, being developed by clinical stage biotechnology company, Faron Pharmaceuticals.